Athinodoros Nikitopoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Athinodoros Nikitopoulos has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Georgios E. Papadopoulos
Cardiology Department Interbalkan Medical Center Thessaloniki Greece
4 shared publications - Ilias Ninios
Cardiology Department Interbalkan Medical Center Thessaloniki Greece
4 shared publications - Sotirios Evangelou
Cardiology Department, Interbalkan Medical Center, Thessaloniki, Greece, Greece
4 shared publications - Vlasis Ninios
Cardiology Department Interbalkan Medical Center Thessaloniki Greece
4 shared publications - Andreas Ioannides
Cardiology Department, Interbalkan Medical Center, Thessaloniki57001, Greece
2 shared publications - Andreas Ioannidis
2nd Cardiology Department, Interbalkan Medical Center, Thessaloniki, Greece, Greece
2 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 8035
High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention: How to Choose the Optimal Antithrombotic Therapy, Its Duration and the Right Stent; A Comprehensive Review of the Current Literature and Proposed Treatment Algorithms
High bleeding risk (HBR) patients represent a significant proportion of those who undergo percutaneous coronary interventions (PCI). The accurate diagnosis of the HBR population is essential because they suffer significantly higher rates of mortality and bleeding compared with non-HBR patients. Although many bleeding risk scores have been developed, the Academic Research Consortium for HBR (ARC–HBR) criteria have established their superiority over the others. In HBR patients without an indication for oral anticoagulant (OAC), shortening the duration of dual antiplatelet therapy (DAPT) is an effective way to minimize bleeding complications in HBR patients with chronic coronary syndromes (CCS). In cases of an acute coronary syndrome (ACS) however, HBR patients combine increased thrombotic burden with an augmented risk of bleeding. Early antiplatelet interruption could result in stent thrombosis with catastrophic consequences. Therefore, in HBR patients with an ACS choosing the optimal DAPT duration, the right P2Y12 inhibitor and the correct time for de-escalation from a potent P2Y12 inhibitor to clopidogrel are of paramount importance. Similar considerations apply to patients with an OAC indication who, according to the ARC–HBR criteria, are HBR. Although new-generation drug-eluting stents (DES) have been developed to induce faster stent endothelization, only few DES have been examined in a HBR population, and these stents should be preferred. The aim of this review is to present the current knowledge of the HBR population and provide comprehensive algorithms to optimally treat HBR patients who undergo PCI with or without an OAC indication and for both ACS and CCS.
- 16 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 8035
Open AccessHigh Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention: How to Choose the Optimal Antithrombotic Therapy, Its Duration and the Right Stent; A Comprehensive Review of the Current Literature and Proposed Treatment Algorithms
High bleeding risk (HBR) patients represent a significant proportion of those who undergo percutaneous coronary interventions (PCI). The accurate diagnosis of the HBR population is essential because they suffer significantly higher rates of mortality and bleeding compared with non-HBR patients. Although many bleeding risk scores have been developed, the Academic Research Consortium for HBR (ARC–HBR) criteria have established their superiority over the others. In HBR patients without an indication for oral anticoagulant (OAC), shortening the duration of dual antiplatelet therapy (DAPT) is an effective way to minimize bleeding complications in HBR patients with chronic coronary syndromes (CCS). In cases of an acute coronary syndrome (ACS) however, HBR patients combine increased thrombotic burden with an augmented risk of bleeding. Early antiplatelet interruption could result in stent thrombosis with catastrophic consequences. Therefore, in HBR patients with an ACS choosing the optimal DAPT duration, the right P2Y12 inhibitor and the correct time for de-escalation from a potent P2Y12 inhibitor to clopidogrel are of paramount importance. Similar considerations apply to patients with an OAC indication who, according to the ARC–HBR criteria, are HBR. Although new-generation drug-eluting stents (DES) have been developed to induce faster stent endothelization, only few DES have been examined in a HBR population, and these stents should be preferred. The aim of this review is to present the current knowledge of the HBR population and provide comprehensive algorithms to optimally treat HBR patients who undergo PCI with or without an OAC indication and for both ACS and CCS.
- Open Access
- 1 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3462
Transfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient
Background/Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is an established treatment for failed surgical aortic bioprostheses, but dedicated data on the MyVal platform remain limited. We evaluated outcomes, hemodynamics, residual gradient, and an exploratory matched comparison with ACURATE neo2. Methods: This prospective, single-center cohort included consecutive patients with failed surgical aortic bioprostheses treated with MyVal ViV-TAVI between July 2022 and June 2025. Outcomes were reported according to VARC-3. Results: Sixty-eight patients were included (age 77 ± 7 years; 51.5% women; EuroSCORE II 7.3 ± 1.8%). Technical success was 100%, with no 30-day death, stroke, myocardial infarction, second-valve implantation, or emergency surgical conversion. Mean gradient decreased from 38.0 ± 9.5 mmHg at baseline to 6.7 ± 2.1 mmHg post-procedure and remained low at 1 year (8.1 ± 2.5 mmHg; overall p < 0.001). AVA increased from 0.80 ± 0.23 cm2 to 1.98 ± 0.19 cm2 post-procedure and was 1.86 ± 0.23 cm2 at 1 year (overall p < 0.001). Smaller true internal diameter independently predicted elevated 1-year gradient (adjusted OR per 1-mm decrease 1.33, 95% CI 1.04–1.78; p = 0.028). In the exploratory matched comparison, safety and hemodynamic outcomes did not differ significantly between MyVal and ACURATE neo2. At a median follow-up of 12.8 months, all-cause mortality and heart failure hospitalization were each 4.4%. Conclusions: In this prospective single-center cohort, MyVal ViV-TAVI was associated with high procedural success and favorable 1-year hemodynamic outcomes, with residual gradient driven mainly by small surgical valve true internal diameter.
- 1 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3462
Open AccessTransfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient
Background/Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is an established treatment for failed surgical aortic bioprostheses, but dedicated data on the MyVal platform remain limited. We evaluated outcomes, hemodynamics, residual gradient, and an exploratory matched comparison with ACURATE neo2. Methods: This prospective, single-center cohort included consecutive patients with failed surgical aortic bioprostheses treated with MyVal ViV-TAVI between July 2022 and June 2025. Outcomes were reported according to VARC-3. Results: Sixty-eight patients were included (age 77 ± 7 years; 51.5% women; EuroSCORE II 7.3 ± 1.8%). Technical success was 100%, with no 30-day death, stroke, myocardial infarction, second-valve implantation, or emergency surgical conversion. Mean gradient decreased from 38.0 ± 9.5 mmHg at baseline to 6.7 ± 2.1 mmHg post-procedure and remained low at 1 year (8.1 ± 2.5 mmHg; overall p < 0.001). AVA increased from 0.80 ± 0.23 cm2 to 1.98 ± 0.19 cm2 post-procedure and was 1.86 ± 0.23 cm2 at 1 year (overall p < 0.001). Smaller true internal diameter independently predicted elevated 1-year gradient (adjusted OR per 1-mm decrease 1.33, 95% CI 1.04–1.78; p = 0.028). In the exploratory matched comparison, safety and hemodynamic outcomes did not differ significantly between MyVal and ACURATE neo2. At a median follow-up of 12.8 months, all-cause mortality and heart failure hospitalization were each 4.4%. Conclusions: In this prospective single-center cohort, MyVal ViV-TAVI was associated with high procedural success and favorable 1-year hemodynamic outcomes, with residual gradient driven mainly by small surgical valve true internal diameter.
- Open Access
- 8 April 2026
- Published by MDPI AG in Preprints.org
Transfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient
Background/Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is an established treatment for failed surgical aortic bioprostheses, but dedicated data on the MyVal platform remain limited. We evaluated outcomes, hemodynamics, residual gradient, and an exploratory matched comparison with ACURATE neo2. Methods: This prospective, single-center cohort included consecutive patients with failed surgical aortic bioprostheses treated with MyVal ViV-TAVI between July 2022 and June 2025. Outcomes were reported according to VARC-3. Results: Sixty-eight patients were included (age 77 ± 7 years; 51.5% women; EuroSCORE II 7.3 ± 1.8%). Technical success was 100%, with no 30-day death, stroke, myocardial infarction, second-valve implantation, or emergency surgical conversion. Mean gradient decreased from 38.0 ± 9.5 mmHg at baseline to 6.7 ± 2.1 mmHg post-procedure and remained low at 1 year (8.1 ± 2.5 mmHg; overall pConclusions: MyVal ViV-TAVI showed high procedural success and durable 1-year hemodynamic performance, with residual gradient driven mainly by small surgical valve true internal diameter.
- 8 April 2026
- Published by MDPI AG in Preprints.org
Open AccessTransfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient
Background/Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is an established treatment for failed surgical aortic bioprostheses, but dedicated data on the MyVal platform remain limited. We evaluated outcomes, hemodynamics, residual gradient, and an exploratory matched comparison with ACURATE neo2. Methods: This prospective, single-center cohort included consecutive patients with failed surgical aortic bioprostheses treated with MyVal ViV-TAVI between July 2022 and June 2025. Outcomes were reported according to VARC-3. Results: Sixty-eight patients were included (age 77 ± 7 years; 51.5% women; EuroSCORE II 7.3 ± 1.8%). Technical success was 100%, with no 30-day death, stroke, myocardial infarction, second-valve implantation, or emergency surgical conversion. Mean gradient decreased from 38.0 ± 9.5 mmHg at baseline to 6.7 ± 2.1 mmHg post-procedure and remained low at 1 year (8.1 ± 2.5 mmHg; overall pConclusions: MyVal ViV-TAVI showed high procedural success and durable 1-year hemodynamic performance, with residual gradient driven mainly by small surgical valve true internal diameter.
- Open Access
- 2 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4677
Efficacy and Safety of ACURATE neo2 in Valve-in-Valve TAVI: A Prospective Single-Center Study
Background/Objectives: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a key approach for treating degenerated surgical bioprosthetic valves. The ACURATE neo2 valve, with its advanced sealing technology and optimized coronary access, represents a promising solution for the challenges of ViV TAVI. This study evaluates the procedural and 30-day and 1-year follow-up outcomes of the ACURATE neo2 valve in ViV TAVI. Methods: This single-center, single-operator prospective study included patients with symptomatic bioprosthetic valve dysfunction, classified in New York Heart Association (NYHA) class III or IV, who underwent ViV TAVI with ACURATE neo2 at our center between July 2022 and February 2024. Outcomes were assessed using VARC-3 criteria. Results: Fifty-five patients (51% females, median (IQR) age 76 (8) years) were included. The technical success rate was 98.2%. No patients experienced in-hospital mortality, stroke, MI, bleeding, vascular complications, renal failure, or new pacemaker implantation. Three patients (5.5%) underwent elective chimney stenting for coronary protection. The postprocedural mean aortic gradient was 6.7 ± 1 mmHg, with a mean aortic valve area (AVA) of 2.0 ± 0.1 cm2. Over a median follow-up period of 1.2 years, no deaths (0%) were observed, heart failure hospitalization rate was 3.6%, and NYHA class improved to ≤II in 100% of patients. Conclusions: ACURATE neo2 demonstrated excellent technical success, sustained hemodynamic performance, and significant clinical improvement in ViV TAVI. The absence of major adverse events reinforces its safety, efficacy, and durability as a treatment for degenerated surgical bioprostheses.
- 2 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4677
Open AccessEfficacy and Safety of ACURATE neo2 in Valve-in-Valve TAVI: A Prospective Single-Center Study
Background/Objectives: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a key approach for treating degenerated surgical bioprosthetic valves. The ACURATE neo2 valve, with its advanced sealing technology and optimized coronary access, represents a promising solution for the challenges of ViV TAVI. This study evaluates the procedural and 30-day and 1-year follow-up outcomes of the ACURATE neo2 valve in ViV TAVI. Methods: This single-center, single-operator prospective study included patients with symptomatic bioprosthetic valve dysfunction, classified in New York Heart Association (NYHA) class III or IV, who underwent ViV TAVI with ACURATE neo2 at our center between July 2022 and February 2024. Outcomes were assessed using VARC-3 criteria. Results: Fifty-five patients (51% females, median (IQR) age 76 (8) years) were included. The technical success rate was 98.2%. No patients experienced in-hospital mortality, stroke, MI, bleeding, vascular complications, renal failure, or new pacemaker implantation. Three patients (5.5%) underwent elective chimney stenting for coronary protection. The postprocedural mean aortic gradient was 6.7 ± 1 mmHg, with a mean aortic valve area (AVA) of 2.0 ± 0.1 cm2. Over a median follow-up period of 1.2 years, no deaths (0%) were observed, heart failure hospitalization rate was 3.6%, and NYHA class improved to ≤II in 100% of patients. Conclusions: ACURATE neo2 demonstrated excellent technical success, sustained hemodynamic performance, and significant clinical improvement in ViV TAVI. The absence of major adverse events reinforces its safety, efficacy, and durability as a treatment for degenerated surgical bioprostheses.
- Open Access
- 27 May 2025
- Published by MDPI AG in Preprints.org
Efficacy and Safety of ACURATE neo2 in Valve‐in‐Valve TAVI: A Prospective Single‐Center Study
Background/Objectives: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a key approach for treating degenerated surgical bioprosthetic valves. The ACURATE neo2 valve, with its advanced sealing technology and optimized coronary access, represents a promising solution for the challenges of ViV TAVI. This study evaluates the procedural and short-to-mid-term outcomes of the ACURATE neo2 valve in ViV TAVI. Methods: This single-center, single-operator prospective study included patients with symptomatic bioprosthetic valve dysfunction, classified in New York Heart Association (NYHA) class III or IV, who underwent ViV TAVI with ACURATE neo2 at our center between July 2022 and February 2024. Outcomes were assessed using VARC-3 criteria. Results: Fifty-five patients (51% females, median (IQR) age 76 (8) years) were included. The technical success rate was 98.2%. No patients experienced in-hospital mortality, stroke, MI, bleeding, vascular complications, renal failure, or new pacemaker implantation. Three patients (5.5%) underwent elective chimney stenting for coronary protection. The post-procedural mean aortic gradient was 6.7 ± 1 mmHg, with a mean aortic valve area (AVA) of 2.0 ± 0.1 cm². Over a median follow-up period of 1.2 years, no deaths (0%) were observed, heart failure hospitalization rate was 3.6%, and NYHA class improved to ≤ II in 100% of patients. Conclusions: ACURATE neo2 demonstrated excellent technical success, sustained hemodynamic performance, and significant clinical improvement in ViV TAVI. The absence of major adverse events reinforces its safety, efficacy, and durability as a treatment for degenerated surgical bioprostheses.
- 27 May 2025
- Published by MDPI AG in Preprints.org
Open AccessEfficacy and Safety of ACURATE neo2 in Valve‐in‐Valve TAVI: A Prospective Single‐Center Study
Background/Objectives: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a key approach for treating degenerated surgical bioprosthetic valves. The ACURATE neo2 valve, with its advanced sealing technology and optimized coronary access, represents a promising solution for the challenges of ViV TAVI. This study evaluates the procedural and short-to-mid-term outcomes of the ACURATE neo2 valve in ViV TAVI. Methods: This single-center, single-operator prospective study included patients with symptomatic bioprosthetic valve dysfunction, classified in New York Heart Association (NYHA) class III or IV, who underwent ViV TAVI with ACURATE neo2 at our center between July 2022 and February 2024. Outcomes were assessed using VARC-3 criteria. Results: Fifty-five patients (51% females, median (IQR) age 76 (8) years) were included. The technical success rate was 98.2%. No patients experienced in-hospital mortality, stroke, MI, bleeding, vascular complications, renal failure, or new pacemaker implantation. Three patients (5.5%) underwent elective chimney stenting for coronary protection. The post-procedural mean aortic gradient was 6.7 ± 1 mmHg, with a mean aortic valve area (AVA) of 2.0 ± 0.1 cm². Over a median follow-up period of 1.2 years, no deaths (0%) were observed, heart failure hospitalization rate was 3.6%, and NYHA class improved to ≤ II in 100% of patients. Conclusions: ACURATE neo2 demonstrated excellent technical success, sustained hemodynamic performance, and significant clinical improvement in ViV TAVI. The absence of major adverse events reinforces its safety, efficacy, and durability as a treatment for degenerated surgical bioprostheses.